tetano
Editor, Senior Moderator
Trends Biotechnol
. 2026 Jun 18:S0167-7799(26)00238-6.
doi: 10.1016/j.tibtech.2026.05.025. Online ahead of print.
Engineered Bacillus subtilis to deliver dsRNA via extracellular vesicles against the H9N2 avian influenza virus
Jiachen Liu[SUP] 1 [/SUP], Yimeng Yang[SUP] 2 [/SUP], Yichao Ma[SUP] 3 [/SUP], Xinming Qin[SUP] 2 [/SUP], Yaotang Wu[SUP] 4 [/SUP], Shubin Li[SUP] 2 [/SUP], Yunlei Cao[SUP] 2 [/SUP], Jian Lin[SUP] 5 [/SUP], Qian Yang[SUP] 2 [/SUP]
Affiliations
RNA interference (RNAi) is a potent antiviral approach, outperforming traditional pesticides and broad-spectrum drugs. Its use in animal disease control faces two challenges: inefficient target design relying on computer-predicted small-interfering RNAs (siRNAs) rather than virus-derived siRNAs (vsiRNAs), and the lack of cost-effective siRNA delivery systems. In this study, we address both limitations by engineering a probiotic Bacillus subtilis 168 strain, called the recombinant B. subtilis AAD (Anti-AIV-DsRNA, targeted AIV), that constitutively expresses vsiRNA-enriched dsRNA targeting the H9N2 avian influenza virus. Oral administration of AAD leads to the release of double-stranded RNA (dsRNA)-loaded extracellular vesicles (EVs), which efficiently reduce H9N2 viral loads and mitigate pathological lesions. Mechanistically, virus-derived dsRNA is processed by the enzyme Dicer into siRNAs, which then activate RNAi and interferon signaling, resulting in approximately a 70% reduction in viral burden. Overall, these findings demonstrate that integrating the probiotic properties of B. subtilis with EV-mediated dsRNA delivery constitutes a sustainable, effective, and residue-free antiviral strategy for animal disease.
Keywords: Bacillus subtilis; H9N2; RNAi; extracellular vesicles.
. 2026 Jun 18:S0167-7799(26)00238-6.
doi: 10.1016/j.tibtech.2026.05.025. Online ahead of print.
Engineered Bacillus subtilis to deliver dsRNA via extracellular vesicles against the H9N2 avian influenza virus
Jiachen Liu[SUP] 1 [/SUP], Yimeng Yang[SUP] 2 [/SUP], Yichao Ma[SUP] 3 [/SUP], Xinming Qin[SUP] 2 [/SUP], Yaotang Wu[SUP] 4 [/SUP], Shubin Li[SUP] 2 [/SUP], Yunlei Cao[SUP] 2 [/SUP], Jian Lin[SUP] 5 [/SUP], Qian Yang[SUP] 2 [/SUP]
Affiliations
- PMID: 42315362
- DOI: 10.1016/j.tibtech.2026.05.025
RNA interference (RNAi) is a potent antiviral approach, outperforming traditional pesticides and broad-spectrum drugs. Its use in animal disease control faces two challenges: inefficient target design relying on computer-predicted small-interfering RNAs (siRNAs) rather than virus-derived siRNAs (vsiRNAs), and the lack of cost-effective siRNA delivery systems. In this study, we address both limitations by engineering a probiotic Bacillus subtilis 168 strain, called the recombinant B. subtilis AAD (Anti-AIV-DsRNA, targeted AIV), that constitutively expresses vsiRNA-enriched dsRNA targeting the H9N2 avian influenza virus. Oral administration of AAD leads to the release of double-stranded RNA (dsRNA)-loaded extracellular vesicles (EVs), which efficiently reduce H9N2 viral loads and mitigate pathological lesions. Mechanistically, virus-derived dsRNA is processed by the enzyme Dicer into siRNAs, which then activate RNAi and interferon signaling, resulting in approximately a 70% reduction in viral burden. Overall, these findings demonstrate that integrating the probiotic properties of B. subtilis with EV-mediated dsRNA delivery constitutes a sustainable, effective, and residue-free antiviral strategy for animal disease.
Keywords: Bacillus subtilis; H9N2; RNAi; extracellular vesicles.